4.7 Article

Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial

Journal

CLINICAL INFECTIOUS DISEASES
Volume 63, Issue 8, Pages 999-1006

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciw451

Keywords

hematopoietic stem cell transplant; infection; prevention; parainfluenza virus; surgical mask

Funding

  1. National Institutes of Health [2P-01 CA47741, T32 HL007057-37, 5KL2TR001115-03, T32 AI007001, 1KL2TR001109]
  2. American Society of Hematology

Ask authors/readers for more resources

Background. Respiratory viral infections (RVIs) are frequent complications of hematopoietic stem cell transplant (HSCT). Surgical masks are a simple and inexpensive intervention that may reduce nosocomial spread. Methods. In this prospective single-center study, we instituted a universal surgical mask policy requiring all individuals with direct contact with HSCT patients to wear a surgical mask, regardless of symptoms or season. The primary endpoint was the incidence of RVIs in the mask period (2010-2014) compared with the premask period (2003-2009). Results. RVIs decreased from 10.3% (95/920 patients) in the premask period to 4.4% (40/911) in the mask period (P<.001). Significant decreases occurred after both allogeneic (64/378 [16.9%] to 24/289 [8.3%], P=.001) and autologous (31/542 [5.7%] to 16/622 [2.6%], P=.007) transplants. After adjusting for multiple covariates including season and year in a segmented longitudinal analysis, the decrease in RVIs remained significant, with risk of RVI of 0.4 in patients in the mask group compared with the premask group (0.19-0.85, P=.02). In contrast, no decrease was observed during this same period in an adjacent hematologic malignancy unit, which followed the same infection control practices except for the mask policy. The majority of this decrease was in parainfluenza virus 3 (PIV3) (8.3% to 2.2%, P<.001). Conclusions. Requiring all individuals with direct patient contact to wear a surgical mask is associated with a reduction in RVIs, particularly PIV3, during the most vulnerable period following HSCT.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available